Clinical trial · Interventional
Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC)
Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Unable to enroll adequate number of participants
Summary
Brief summary (as posted)
This project proposes to use bronchoscopic intratumoral chemotherapy for small cell lung cancer in two fashions: 1. to implement a prospective clinical trial to test the feasibility and efficacy of intralesional chemotherapy as consolidative therapy immediately following standard systemic chemotherapy and radiation therapy for patients with limited stage SCLC by comparing tumor growth and survival rates of the treatment group and compare the outcomes to historical controls 2. to implement a prospective clinical trial to test the feasibility and efficacy as measured by tumor growth and survival rates of intralesional chemotherapy for patients with recurrent SCLC after standard treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small Cell Lung Cancer | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin | Drug | Cisplatin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- patients with limited stage SCLC
- description
- Subjects with limited stage SCLC treated sequentially with cisplatin.
- interventionNames
- Drug: Cisplatin
- type
- NO_INTERVENTION
- label
- Historical Controls
- description
- No intervention
Primary outcomes (1)
- measure
- Solid Tumor Growth After Completion of Interventional Bronchoscopies
- timeFrame
- 18 months
- description
- The Organization for Research and Treatment of Cancer Response Evaluation Criteria in Solid Tumors (RECIST) system will be used to grade the response to therapy.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: Competent adult English speaking subjects * With limited stage SCLC who have completed standard of care treatment who are responders with no evidence of disseminated disease other than CNS metastasis, * With recurrent disseminated SCLC after standard of care treatment with symptoms related to central tumor obstruction, * With recurrent limited stage SCLC with mediastinal/hilar recurrence not previously treated with intratumoral cisplatin Exclusion Criteria: * Subjects who do not meet the inclusion criteria * Subjects who, in the opinion of the investigator, are at risk undergoing a bronchoscopy
References
Publications (0)
Data not yet available